Neurostimulation effective for management of chronic pain

St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced two-year results in a post-market clinical study evaluating neurostimulation (spinal cord stimulation) for the management of chronic low back pain. Presented at the 14th annual North American Neuromodulation Society (NANS) meeting in Las Vegas, the study found that 70 percent of neurostimulation patients reported overall pain relief of 50 percent or better at their final two-year visit. Additionally, 88 percent of these patients reported that their quality of life was improved or greatly improved.

“There is a growing body of evidence that confirms the effectiveness of neurostimulation for the management of chronic pain, especially for those patients who have tried multiple therapies only to continue to suffer with pain”

"This study is the largest neurostimulation study conducted to date and is specifically designed to gather more information about the effectiveness of spinal cord stimulation for low back pain," said Dr. Eugene Mironer, presenter of the results and managing partner of the Carolina Center for Advanced Management of Pain in Spartanburg, S.C. "Our findings at the two-year mark indicate that the therapy is sustainable long-term. In addition to reporting an improvement in their quality of life, 89 percent of patients were satisfied or very satisfied with their results."

Neurostimulation therapy is a proven method of managing chronic pain. It uses an implantable medical device to deliver mild electrical pulses to the epidural space to mask or interrupt pain signals as they travel to the brain. St. Jude Medical is sponsoring this research to continue to build on the published data supporting the long-term sustainability of the therapy.

"There is a growing body of evidence that confirms the effectiveness of neurostimulation for the management of chronic pain, especially for those patients who have tried multiple therapies only to continue to suffer with pain," said Chris Chavez, president of the St. Jude Medical Neuromodulation Division. "Over the course of the past decade, physician training, technology improvement and patient selection criteria have advanced greatly. Our study validates the significant impact of these advances in further improving the effectiveness of neurostimulation therapy."

The large scale, prospective study was conducted at 29 medical centers across the U.S. Preliminary analysis presented at NANS includes data from 130 patients that have met the two-year follow-up point, since not all patients have reached the two-year evaluation mark. The study design utilizes the Eon™ rechargeable spinal cord stimulator and dual or tripolar arrays of percutaneous leads or surgical leads.

Pain affects millions of people worldwide. In the U.S., more than 76.5 million people are categorized as suffering from pain by the American Pain Foundation. Estimates by the National Institutes of Health place the costs for lost work time and healthcare expenses at approximately $100 billion every year.

For more than 30 years, the St. Jude Medical Neuromodulation Division has developed new technologies to manage chronic pain and other neurological disorders. Today more than 75,000 patients in 40 countries have been implanted with St. Jude Medical neurostimulation systems.

Source:

St. Jude Medical

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
SARS-CoV-2 spike protein may induce analgesia